Last updated: August 22, 2026
Hydroxychloroquine sulfate is a mature, multisource small-molecule drug with limited composition-of-matter protection and no biosimilar pathway. Commercial value is concentrated in manufacturing efficiency, dosage-form differentiation, pediatric access, supply reliability, and regulatory execution rather than conventional patent exclusivity.
The strongest opportunities are a palatable oral liquid, a robust low-cost tablet platform, dose-flexible products for pediatric and rheumatology use, and contract manufacturing for markets with limited local supply. The principal technical constraints are bitterness, dose accuracy, tablet quality, excipient compatibility, and the drug's narrow safety margin in overdose.
What is the FDA regulatory status of hydroxychloroquine sulfate?
Hydroxychloroquine sulfate is FDA-approved in oral tablet form for malaria treatment and suppression, rheumatoid arthritis, and systemic lupus erythematosus and discoid lupus erythematosus [1]. Plaquenil is the reference product marketed by Sanofi, while multiple manufacturers supply generic hydroxychloroquine sulfate tablets.
Hydroxychloroquine is not FDA-approved for prevention or treatment of COVID-19. The FDA revoked its emergency use authorization in June 2020 after concluding that the statutory criteria for emergency use were no longer met [2].
Key FDA regulatory facts
| Item |
Status |
| Active ingredient |
Hydroxychloroquine sulfate |
| Reference product |
Plaquenil tablets |
| Principal dosage strengths |
200 mg tablets; equivalent to 155 mg hydroxychloroquine base |
| FDA-approved routes |
Oral |
| Approved therapeutic areas |
Malaria, rheumatoid arthritis, lupus |
| FDA-approved liquid |
No widely established FDA reference product equivalent to the standard tablet |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
ANDA under section 505(j) |
| COVID-19 approval |
None |
| Regulatory exclusivity |
No meaningful current exclusivity barrier identified for the mature reference product |
The 200 mg sulfate tablet contains approximately 155 mg of hydroxychloroquine base. This conversion matters for liquid development, pediatric dosing, labeling, and international product comparisons.
What patents protect hydroxychloroquine sulfate?
Hydroxychloroquine sulfate has no commercially significant unexpired composition-of-matter patent estate comparable to that of a recently launched drug. The active ingredient and conventional tablet technology are mature, and generic competition has existed for many years.
The principal commercial protection is therefore regulatory and manufacturing-based rather than patent-based.
Patent and exclusivity position
| Protection category |
Commercial assessment |
| Composition-of-matter patent |
Expired or commercially irrelevant |
| Conventional tablet formulation patents |
No significant active barrier identified for standard generic tablets |
| Method-of-use patents |
Historical use claims do not create a meaningful barrier to approved generic indications |
| FDA orphan exclusivity |
Not identified as a current commercial barrier |
| Pediatric exclusivity |
No current exclusivity barrier identified |
| Reference-product exclusivity |
Expired for the mature product |
| Biosimilar exclusivity |
Not applicable |
| Trade secrets |
Potentially relevant to process yield, impurity control, and formulation robustness |
| Data exclusivity |
Not commercially material for this established product |
A company filing a new hydroxychloroquine sulfate product should still conduct a current Orange Book and patent-certification review. A Paragraph IV filing becomes relevant only if the ANDA applicant identifies an applicable listed patent and seeks approval before its expiration. For a standard tablet, the principal risks are more likely to involve regulatory deficiency, product quality, or supply execution than a blocking patent.
What is the Orange Book status of hydroxychloroquine sulfate?
Hydroxychloroquine sulfate tablets are genericized products associated with the Plaquenil reference product. The Orange Book framework remains relevant for identifying the reference listed drug, therapeutic equivalence codes, dosage forms, and any listed patents or exclusivity.
For a conventional 200 mg tablet, the commercial pathway is generally an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the applicable reference product. The FDA's Orange Book and Drugs@FDA databases should be used for the filing-specific determination of listed patents, reference product status, and approved manufacturers [3,4].
A new dosage form, such as a liquid, chewable tablet, or orally disintegrating tablet, may not qualify for a simple generic substitution pathway if it lacks a suitable reference product. The sponsor may need a 505(b)(2) application supported by bridging studies, comparative bioavailability data, stability data, and a justification for the new dosage form.
What excipients are used in hydroxychloroquine sulfate tablets?
The excipient profile varies by manufacturer. The Plaquenil label identifies common tablet ingredients such as dibasic calcium phosphate dihydrate, corn starch, magnesium stearate, hypromellose, polyethylene glycol, polysorbate 80, and titanium dioxide, although generic products use different combinations [1].
Representative excipient functions
| Excipient class |
Typical examples |
Function |
| Diluent |
Dibasic calcium phosphate, microcrystalline cellulose, lactose |
Provides tablet mass and improves compression |
| Disintegrant |
Corn starch, crospovidone, sodium starch glycolate |
Promotes tablet breakup |
| Binder |
Povidone, pregelatinized starch, hypromellose |
Improves granule and tablet strength |
| Lubricant |
Magnesium stearate |
Reduces tooling friction |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow |
| Film former |
Hypromellose |
Protects the core and improves swallowability |
| Plasticizer |
Polyethylene glycol |
Supports coating flexibility |
| Surfactant |
Polysorbate 80 |
Supports coating or wetting performance |
| Opacifier and colorant |
Titanium dioxide, approved colorants |
Supports product appearance and light protection |
The best excipient system depends on the manufacturing process. Direct compression can reduce processing steps but may create flow and content-uniformity challenges. Wet granulation can improve blend uniformity and compactability but adds drying, scale-up, and residual-moisture controls.
How should an excipient strategy address hydroxychloroquine sulfate formulation risks?
The formulation should prioritize dose uniformity, rapid and reproducible disintegration, mechanical strength, low friability, and acceptable taste after swallowing. Hydroxychloroquine tablets are often taken chronically, so coating quality and swallowability influence adherence.
Tablet strategy
A conventional immediate-release tablet can use a calcium phosphate or microcrystalline cellulose diluent system with starch-based or superdisintegrant technology. The formulation should be evaluated for:
- Blend segregation during high-speed compression
- Assay and content uniformity across tablet weight ranges
- Lubricant sensitivity, especially with magnesium stearate
- Disintegration after film coating
- Dissolution robustness across pH conditions
- Moisture-related changes in hardness and dissolution
- Stability of the sulfate salt under accelerated conditions
A lower-cost product may use a simple, widely available excipient platform. A premium generic can differentiate through smaller tablet dimensions, scoreability, improved coating, or a broader range of strengths.
Taste and oral-liquid strategy
Hydroxychloroquine is bitter. A liquid product requires more than simple dispersion of crushed tablets. It needs controlled solubilization or suspension, taste masking, preservative selection, dose-uniformity testing, and container-closure compatibility.
Potential approaches include:
- Sweetener and flavor systems
- Ion-exchange resin complexation
- Polymer-based taste masking
- Film-coated microparticles suspended in a vehicle
- pH adjustment to improve palatability and stability
- Suspending agents such as xanthan gum or cellulose derivatives
- Preservatives appropriate for the selected pH and multidose packaging
A suspension can reduce chemical exposure to the taste receptors, but it creates sedimentation, redispersibility, microbial, and dose-withdrawal risks. A solution may provide better dose uniformity but can intensify bitterness and increase the need for taste masking.
The commercial target is a stable, ready-to-use product with a calibrated oral syringe. Pediatric caregivers and pharmacies often value dosing accuracy more than a modest reduction in manufacturing cost.
What formulations are commercially attractive for hydroxychloroquine sulfate?
The strongest opportunities are dosage forms that solve practical administration problems without creating unnecessary clinical or regulatory complexity.
Pediatric oral liquid
A pediatric liquid is the clearest formulation opportunity. Hydroxychloroquine is used in pediatric malaria and autoimmune disease, but conventional 200 mg tablets are poorly suited to weight-based dosing. A commercial liquid could provide:
- Accurate weight-based dosing
- Reduced tablet manipulation
- Improved access for children and patients with dysphagia
- Lower compounding burden for pharmacies
- Potential global-health utility in malaria-endemic regions
The product must address concentration selection. A highly concentrated liquid reduces administration volume but increases the risk of a serious dosing error. A lower concentration improves dose flexibility but raises packaging, shipping, and excipient costs.
Scored or smaller tablets
A smaller tablet, an improved score line, or multiple low-dose strengths could support pediatric and geriatric use. The sponsor would need to demonstrate that splitting produces acceptable dose uniformity if the label supports tablet division.
Chewable or orally disintegrating tablet
A chewable or orally disintegrating dosage form could address swallowing difficulty and improve adherence. Bitterness makes these products technically difficult. Taste masking must remain effective throughout shelf life, and the product must avoid rapid drug release in the mouth.
Unit-dose packaging
Unit-dose blister packaging can reduce medication errors, support institutional dispensing, and improve protection from moisture. It also allows manufacturers to sell dose packs for malaria treatment or titration regimens.
Modified-release products
Modified-release hydroxychloroquine is a weaker initial opportunity. The drug's established dosing, chronic-use indications, and relatively low unit cost may not justify the clinical and regulatory burden of a new release profile. A modified-release product would need a clear benefit, such as reduced dosing frequency or improved tolerability.
How strong is the patent estate for hydroxychloroquine sulfate formulations?
The patent estate is weak for conventional tablets and potentially stronger for genuinely differentiated delivery systems.
| Product concept |
Likely patent potential |
Development risk |
Commercial attractiveness |
| Standard 200 mg immediate-release tablet |
Low |
Low to moderate |
Moderate |
| Low-cost generic tablet |
Low |
Low |
Moderate at scale |
| Pediatric oral suspension |
Moderate |
Moderate |
High |
| Taste-masked multiparticulate liquid |
Moderate to high |
High |
High if clinically acceptable |
| Chewable tablet |
Moderate |
Moderate to high |
Moderate |
| Orally disintegrating tablet |
Moderate |
Moderate |
Moderate |
| Modified-release tablet |
Moderate |
High |
Low to moderate |
| Unit-dose blister system |
Low to moderate |
Low |
Moderate |
| Novel fixed-dose combination |
Potentially moderate |
High |
Indication-dependent |
A formulation patent may protect a defined excipient ratio, particle architecture, coating composition, release profile, or stability result. Patent strength depends on claim breadth and the sponsor's ability to show that competitors cannot achieve the same performance with routine excipient substitutions.
A patent claiming only a broad combination of familiar excipients is vulnerable to obviousness and design-around arguments. A stronger filing would link the formulation to measurable performance, such as improved taste-masking duration, stability under tropical conditions, reduced sedimentation, or superior dose uniformity.
What manufacturing and intellectual-property barriers affect hydroxychloroquine sulfate?
Hydroxychloroquine sulfate is not difficult to manufacture relative to complex biologics, but commercial quality control remains important. Key barriers include:
- Control of assay and related substances
- Consistent particle size and flow properties
- Prevention of blend segregation
- Reliable tablet compression at commercial speed
- Stability under heat and humidity
- Coating uniformity
- Cleaning validation for potent active pharmaceutical ingredient
- Supply of qualified active pharmaceutical ingredient
- Compliance with current good manufacturing practice
- Packaging that limits moisture and dosing errors
For a liquid, the technical barrier increases. The manufacturer must control sedimentation, microbial growth, preservative effectiveness, viscosity, redispersibility, and delivered dose from the oral syringe.
In tropical and malaria-endemic markets, stability under elevated temperature and humidity can be commercially decisive. A formulation with a less complex excipient system and strong climatic stability may outperform a technically sophisticated product with higher logistics costs.
When does hydroxychloroquine sulfate lose exclusivity?
Hydroxychloroquine sulfate has already lost practical market exclusivity. The relevant commercial question is not when the original product loses exclusivity, but whether a new formulation can create defensible differentiation.
A standard generic tablet can face immediate multisource competition after approval. A novel 505(b)(2) product may obtain regulatory exclusivity if it meets statutory requirements, but the duration and scope depend on the application, the approved changes, and any applicable exclusivity designation. A formulation patent could extend protection beyond regulatory exclusivity, subject to validity and infringement analysis.
Which companies are challenging hydroxychloroquine sulfate exclusivity?
No single company dominates the challenge because the market is already genericized. Competition comes from multiple generic manufacturers, contract manufacturers, and regional suppliers rather than from a concentrated Paragraph IV campaign.
The main competitive groups are:
- Large generic companies with established oral-solid manufacturing.
- Regional manufacturers serving malaria and autoimmune markets.
- Compounding pharmacies supplying noncommercial liquids.
- Specialty developers pursuing pediatric or taste-masked formulations.
- Contract development and manufacturing organizations offering low-cost formulation development.
The competitive advantage is likely to come from FDA approval, reliable supply, low-cost API sourcing, and differentiated packaging rather than litigation.
What patent litigation and settlement agreements affect hydroxychloroquine sulfate?
Hydroxychloroquine sulfate does not have a major current patent-litigation profile comparable to high-value branded products. No material settlement structure is central to standard generic entry.
For a new formulation, litigation risk could arise from:
- A listed patent associated with a new reference product
- A patent covering taste-masked particles
- A patent covering a liquid vehicle or stabilization system
- A patent covering a modified-release profile
- Trade-secret disputes involving manufacturing parameters
- Product-liability claims linked to dosing errors or excipient intolerance
A sponsor should separate patentability from freedom to operate. A new formulation can be patentable while still potentially infringing an earlier delivery-system patent.
How does hydroxychloroquine sulfate compare with competing drugs?
Hydroxychloroquine competes clinically with other antimalarial and autoimmune therapies, but its excipient opportunity is distinct because it is an old, low-cost oral medicine.
| Product or class |
Formulation position |
Commercial implication |
| Hydroxychloroquine sulfate |
Mature tablets; liquid opportunity |
Low-cost platform with pediatric and access potential |
| Chloroquine phosphate |
Mature oral products |
Similar administration and bitterness issues; different salt and dose conversion |
| Methotrexate |
Tablets and injectable products |
Greater toxicity-management burden; established liquid opportunity |
| Sulfasalazine |
Tablets and suspension products |
More established formulation differentiation |
| Azathioprine |
Tablets and limited liquid access |
Chronic autoimmune competition |
| Newer biologics |
Injectable or infused |
Higher cost, stronger patent estates, different patient segments |
Hydroxychloroquine remains relevant where oral administration, cost, and long-term clinical familiarity matter. Biologics and newer targeted therapies reduce its share in some autoimmune treatment settings, but they do not eliminate demand for hydroxychloroquine in lupus and selected rheumatoid arthritis populations.
What revenue exposure and commercial opportunities exist?
Public companies generally do not report hydroxychloroquine revenue as a separate material segment. Product-level revenue estimates are therefore less reliable than market-wide volume and price analysis.
The commercial model is typically based on high unit volume and low gross margin. Attractive opportunities include:
- FDA-approved generic tablets with dependable supply
- Pediatric liquid products with limited direct competition
- Contract manufacturing for government tenders
- Products adapted to tropical stability requirements
- Unit-dose blister packs for hospitals and public-health programs
- Licensed technology for taste masking or ready-to-use suspensions
- Regional registration packages in countries with limited approved liquid options
The main downside is rapid price erosion after multiple generic approvals. A formulation investment should be supported by either a differentiated regulatory pathway, supply contract, institutional customer, or defensible formulation patent.
What generic launch risks exist for hydroxychloroquine sulfate?
Generic launch risk is moderate for a standard tablet and higher for a novel liquid.
Standard tablet risks
- Intense price competition
- Limited prescriber differentiation
- API supply interruptions
- Dissolution or content-uniformity failures
- Low forecast accuracy
- Retail channel margin pressure
Liquid and pediatric-product risks
- Failure to demonstrate dose uniformity
- Poor taste acceptance
- Sedimentation or caking
- Preservative failure
- Short shelf life
- Dosing errors from concentration confusion
- Higher packaging and distribution costs
- Need for a 505(b)(2) regulatory strategy
A sponsor should avoid launching multiple liquid concentrations unless the clinical and commercial rationale is clear. Concentration proliferation can increase medication errors and complicate pharmacy substitution.
Key Takeaways
- Hydroxychloroquine sulfate is a mature generic drug with no meaningful current composition-of-matter exclusivity.
- Conventional 200 mg tablets are difficult to differentiate through patents alone.
- The most credible formulation opportunity is a palatable, stable, accurately dosed pediatric oral liquid.
- Taste masking, sedimentation control, preservative performance, and oral-syringe dosing are the principal liquid-development challenges.
- Smaller, scored, chewable, or orally disintegrating tablets may support niche differentiation.
- A standard tablet generally follows an ANDA pathway; a novel liquid may require a 505(b)(2) strategy.
- Biosimilar risk is irrelevant because hydroxychloroquine sulfate is a small molecule.
- Manufacturing reliability, tropical stability, API sourcing, and government procurement access may provide greater commercial advantage than patent ownership.
- Commercial returns depend on volume, supply contracts, and formulation differentiation because generic price erosion is substantial.
- A new formulation patent is strongest when tied to measurable performance that competitors cannot easily reproduce through routine excipient substitution.
FAQs About Hydroxychloroquine Sulfate Excipient Commercialization
Can hydroxychloroquine sulfate be formulated as an FDA-approved oral suspension?
Yes. A sponsor can develop an oral suspension, but the regulatory pathway depends on the existence of a suitable reference product and the extent of the formulation change. Comparative bioavailability, stability, microbial control, redispersibility, and dose-delivery studies are central requirements.
Which excipient is best for masking hydroxychloroquine bitterness?
No single excipient is universally best. Ion-exchange resins, polymer coatings, multiparticulates, sweeteners, flavors, and pH control may be combined. The preferred system must be selected through sensory testing, dissolution testing, stability studies, and dose-uniformity evaluation.
Is a hydroxychloroquine sulfate liquid protected by formulation patents?
A liquid can be patentable if it contains a novel and nonobvious composition or delivery system. Broad claims covering routine sweeteners, suspending agents, or preservatives are less defensible than claims tied to a defined taste-masking structure, stability result, or dosing performance.
Does hydroxychloroquine sulfate require a pediatric exclusivity strategy?
A pediatric product may be commercially attractive without pediatric exclusivity. The sponsor's primary value drivers are dosing convenience, approved labeling, pharmacy adoption, and supply access. Any exclusivity depends on the FDA development mechanism and statutory eligibility.
What is the highest-value licensing opportunity in hydroxychloroquine sulfate?
The most credible licensing target is a validated pediatric liquid or taste-masked delivery platform with demonstrated stability, dose accuracy, and regulatory utility. Licensing a conventional tablet excipient formula is less likely to create durable value unless it delivers a measurable manufacturing or stability advantage.
References
-
U.S. Food and Drug Administration. (2023). Plaquenil (hydroxychloroquine sulfate) tablets: Prescribing information. Sanofi-Aventis U.S. LLC.
-
U.S. Food and Drug Administration. (2020). FDA revokes emergency use authorization for chloroquine phosphate and hydroxychloroquine sulfate. https://www.fda.gov
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/
